:TC-2216

{{Short description|Chemical compound}}

{{Context|date=March 2021}}

{{Drugbox

| verifiedrevid = 350296627

| IUPAC_name = 8-pyridin-3-yl-1,8-diazaspiro[4.4]nonane

| image = TC-2216.svg

| width = 240

| tradename =

| routes_of_administration =

| CAS_number_Ref = {{cascite|correct|CAS}}

| CAS_number = 646055-67-6

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = J2T94PE2HD

| ATC_suffix =

| PubChem = 10176607

| ChemSpiderID = 8352112

| C=12 | H=17 | N=3

| smiles = N1CCCC1(CC2)CN2c3cnccc3

| StdInChI = 1S/C12H17N3/c1-3-11(9-13-6-1)15-8-5-12(10-15)4-2-7-14-12/h1,3,6,9,14H,2,4-5,7-8,10H2

| StdInChIKey = NXIPMBQVNTWEEX-UHFFFAOYSA-N

}}

TC-2216 is a drug developed by Targacept which acts as a partial agonist at neural nicotinic acetylcholine receptors and was researched for the treatment of anxiety and depression.{{cite journal | vauthors = Romanelli MN, Gratteri P, Guandalini L, Martini E, Bonaccini C, Gualtieri F | title = Central nicotinic receptors: structure, function, ligands, and therapeutic potential | journal = ChemMedChem | volume = 2 | issue = 6 | pages = 746–67 | date = June 2007 | pmid = 17295372 | doi = 10.1002/cmdc.200600207 | s2cid = 34763474 }} It was unsuccessful as a therapeutic but is still used in pharmacological research as an alpha4beta2-selective antagonist.{{cite journal | vauthors = Lippiello PM, Beaver JS, Gatto GJ, James JW, Jordan KG, Traina VM, Xie J, Bencherif M | title = TC-5214 (S-(+)-mecamylamine): a neuronal nicotinic receptor modulator with antidepressant activity | journal = CNS Neuroscience & Therapeutics | volume = 14 | issue = 4 | pages = 266–77 | date = 2008 | pmid = 19040552 | pmc = 6494058 | doi = 10.1111/j.1755-5949.2008.00054.x }}